1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,900 | 9,200 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST SUBJECT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF PERTUZUMAB AND TRASTUZUMAB INJECTION (SUBCUTANEOUS ... | - | HKEx | ||
| Do | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTARY APPLICATIONS FOR INDICATION EXPANSION OF HANLIKANG (RITUXIMAB INJECTION) APPROVED BY NMPA | - | HKEx | ||
| 01.04. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATIONS FOR THE PHASE 1 CLINICAL TRIALS OF PERTUZUMAB AND TRASTUZUMAB INJECTION ... | - | HKEx | ||
| 31.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLXTE-HAASE02 (RECOMBINANT HUMAN HYALURONIDASE INJECTION) ... | - | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 30.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) ... | - | HKEx | ||
| 26.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1B/2 CLINICAL STUDY OF HLX701 (RECOMBINANT HUMAN SIRPA-IGG4 FC FUSION ... | - | HKEx | ||
| 20.03. | Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations | 251 | PR Newswire | SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its 2025 annual results, marking its third consecutive year of profitability since 2023. During the reporting period... ► Artikel lesen | |
| 20.03. | Shanghai Henlius Biotech Inc. Full Year Sales Increase | 1 | RTTNews | ||
| 20.03. | HENLIUS (02696): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 2 | HKEx | ||
| 20.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ... | 1 | HKEx | ||
| 20.03. | HENLIUS (02696): CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORISED REPRESENTATIVE | 2 | HKEx | ||
| 20.03. | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS - PROMOTIONAL SERVICES AGREEMENT | - | HKEx | ||
| 16.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANISED ... | 2 | HKEx | ||
| 09.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE FC FUSION PROTEIN) ... | - | HKEx | ||
| 09.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX3901 INJECTION (DLL3XDLL3XCD3XCD28 TETRA-SPECIFIC ANTIBODY) FOR ... | 1 | HKEx | ||
| 05.03. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX97 (KAT6A/B SMALL MOLECULE INHIBITOR) FOR THE ... | 1 | HKEx | ||
| 03.03. | HENLIUS (02696): DATE OF BOARD MEETING | - | HKEx | ||
| 02.03. | Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22 | 663 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 2, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed... ► Artikel lesen | |
| 27.02. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - PERTUZUMAB BIOSIMILAR HLX11 (RECOMBINANT ANTI-HER2 DOMAIN II HUMANIZED MONOCLONAL ANTIBODY INJECTION) RECEIVED ... | - | HKEx | ||
| 27.02. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN THE PHASE 2/3 CLINICAL STUDY OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ... | 1 | HKEx |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| BEAM THERAPEUTICS | 27,450 | +4,21 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,000 Euro und damit +4,05 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.